A new approach to treating Alzheimer’s disease, focused on repurposing brain cells to clear damaging amyloid plaques, is showing promising results in early studies. Researchers at Washington University School of Medicine in St. Louis have developed an experimental cellular immunotherapy that, in mice, not only prevented the formation of these plaques but also reduced existing plaque levels by as much as 50%. This research offers a potential path toward a single-injection therapy for Alzheimer’s, a significant improvement over current treatments that require frequent infusions.
Alzheimer’s disease, a progressive neurodegenerative condition, affects millions worldwide. Current treatments, such as monoclonal antibodies like aducanumab and lecanemab, aim to slow the disease’s progression by reducing amyloid beta, a protein that accumulates in the brain and disrupts normal function. However, these therapies require regular intravenous infusions, presenting logistical challenges for patients. The search for more effective and convenient treatments continues, and this new research represents a potentially significant step forward in Alzheimer’s disease therapeutics.
The findings, published March 5 in the journal Science, detail a novel strategy inspired by CAR-T cell therapy, a successful cancer treatment. Instead of modifying immune T cells to attack cancer, the researchers focused on astrocytes, the most abundant type of cell in the brain. They engineered these astrocytes to specifically target and remove amyloid beta plaques.
Turning Brain’s Support Cells into Plaque Destroyers
Astrocytes typically play a supportive role in the brain, maintaining a healthy environment for neurons. The Washington University team, led by Marco Colonna, MD, the Robert Rock Belliveau, MD, Professor of Pathology at WashU Medicine, equipped these cells with a “CAR homing device”—a chimeric antigen receptor—that allows them to latch onto amyloid beta plaques and destroy them. “This study marks the first successful attempt at engineering astrocytes to specifically target and remove amyloid beta plaques in the brains of mice with Alzheimer’s disease,” Colonna said.
The engineered astrocytes essentially act as powerful cleaning cells, concentrating on the removal of harmful proteins that contribute to cognitive decline. This approach aims to bolster the brain’s natural clearance mechanisms, which can become overwhelmed in Alzheimer’s disease. Normally, immune cells called microglia are responsible for removing cellular waste, but their function is often impaired in neurodegenerative conditions.
How the Therapy Works: Reprogramming Astrocytes
The research team, including first author Yun Chen, PhD, focused on astrocytes to reduce the burden on microglia. Chen redesigned the astrocytes to become specialized amyloid-clearing cells by introducing a gene that produces the chimeric antigen receptor (CAR). This gene was delivered using a harmless virus injected into mice. Once expressed on the astrocyte surface, the CAR enabled the cells to capture and engulf amyloid beta proteins.
To test the therapy, the researchers used mice genetically predisposed to develop Alzheimer’s disease, which typically begin forming amyloid plaques around six months of age. They divided the mice into two groups: one received the CAR-gene-carrying virus before plaque formation began, while the other received it after their brains were already filled with plaques. After three months, the results were evaluated.
Promising Results in Mouse Models
In the younger mice, the engineered CAR-astrocytes successfully prevented plaque formation. By six months of age, when untreated mice typically have brains packed with amyloid plaques, the treated mice showed no detectable plaques.
The results were also encouraging in older mice with existing plaques. The therapy reduced amyloid plaque levels by approximately 50% compared to mice that received a control virus without the CAR gene. This suggests the therapy can not only prevent plaque formation but also potentially reverse some of the damage caused by existing plaques.
The researchers have filed a patent related to their CAR-astrocyte engineering method with assistance from the Office of Technology Management at WashU. David M. Holtzman, MD, the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology at WashU Medicine, and a co-author on the paper, emphasized the potential advantages of this approach. “Consistent with the antibody drug treatments, this new CAR-astrocyte immunotherapy is more effective when given in the earlier stages of the disease,” he said. “But where it differs, and where it could make a difference in clinical care, is in the single injection that successfully reduced the amount of harmful brain proteins in mice.”
Looking Ahead: From Mice to Humans and Beyond
While these findings are promising, it’s crucial to remember that the research is still in its early stages. The therapy has only been tested in mice, and significant work remains to optimize the approach and address potential side effects before it can be tested in humans. The research team plans to focus on improving the precision of the cell targeting and ensuring that normal brain cell activity is not disrupted.
Beyond Alzheimer’s disease, researchers believe this technology could be adapted to treat other neurological conditions, including brain tumors. By modifying the CAR homing device to recognize markers found on tumor cells, astrocytes could potentially be redirected to destroy cancerous cells, offering a new avenue for cancer treatment.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next steps for the Washington University team involve further refining the CAR-astrocyte therapy and conducting preclinical studies to assess its safety, and efficacy. The potential for a single-injection treatment for Alzheimer’s disease offers a glimmer of hope for millions affected by this devastating condition.
Have thoughts on this story? Share your comments below and consider sharing this article with your network.
